Roth Resumes Coverage On Fibrocell With Buy Rating, $7 Target

By: via Benzinga
Fibrocell Science Inc (NASDAQ: FCSC) is leveraging its expertise with fibroblasts to target monogenic diseases as well as broader ...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.